How Does Retatrutide Work? The Triple-Action Peptide Explained

Retatrutide represents a potentially transformative advancement in medical weight loss therapy for obesity and metabolic disease. As the first triple hormone receptor agonist to enter clinical development, it has generated substantial interest from researchers, clinicians, and patients alike. In Eli Lilly’s Phase 2 trial, adults on the 12 mg dose lost an average of 24.2% of their body weight in 48 weeks. In the Phase 3 TRIUMPH-1 trial, 2,339 adults without diabetes lost an average of 28.3% on 12 mg at 80 weeks.

This guide explains exactly how retatrutide works, what the clinical data shows, how it compares to existing medications, and what you should know if you are considering it as part of a weight management program.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly and Company that functions as a triple incretin receptor agonist. It simultaneously activates three hormone receptors that play central roles in metabolism, appetite regulation, and energy balance:

1. Glucagon-like peptide-1 (GLP-1) receptor
2. Glucose-dependent insulinotropic polypeptide (GIP) receptor
3. Glucagon receptor

Previous weight loss medications have targeted one or two of these pathways. Semaglutide (Ozempic, Wegovy) acts on GLP-1 alone. Tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP. Retatrutide is the first compound to engage all three receptors simultaneously, creating what researchers describe as a comprehensive metabolic intervention.

The medication is administered as a once-weekly subcutaneous injection. Eli Lilly has now reported results from five Phase 3 trials and plans to submit it for U.S. approval in the first quarter of 2027.

How Retatrutide Works: The Triple Pathway Mechanism

Understanding retatrutide requires understanding the three hormone pathways it activates and how they work together to produce metabolic changes.

GLP-1 Receptor Activation

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by L-cells in the small intestine after eating. It plays several critical roles:

• Appetite suppression — GLP-1 acts on the hypothalamus and brainstem to reduce hunger signals and increase feelings of fullness. Research published in Diabetes has shown that GLP-1 receptor activation in the central nervous system directly reduces food intake (Turton et al., 1996)
• Slowed gastric emptying — GLP-1 delays how quickly food moves from the stomach into the small intestine, prolonging satiety after meals
• Enhanced insulin secretion — GLP-1 stimulates glucose-dependent insulin release from pancreatic beta cells, helping regulate blood sugar without causing hypoglycemia
• Glucagon suppression — Paradoxically, while retatrutide also activates the glucagon receptor directly, GLP-1 pathway activation suppresses inappropriate glucagon release after meals, helping stabilize postprandial blood sugar

This is the same pathway that semaglutide targets, and it accounts for much of the appetite suppression that weight loss medications produce.

GIP Receptor Activation

GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone, released by K-cells in the upper small intestine. Its role in weight management is more complex and was historically underappreciated:

• Insulin sensitization — GIP enhances the insulin response to glucose, improving the body’s ability to manage blood sugar efficiently
• Fat tissue modulation — GIP receptors are expressed on adipocytes (fat cells), and GIP signaling may influence how fat is stored and metabolized; a 2020 review in Trends in Endocrinology & Metabolism describes GIP’s actions on fat tissue as still debated (Samms et al., 2020)
• Synergy with GLP-1 — When GIP and GLP-1 receptors are activated together, the combined effect on appetite suppression and insulin sensitivity exceeds what either achieves alone. This synergistic effect is likely why tirzepatide (a dual GIP/GLP-1 agonist) outperforms semaglutide (GLP-1 only) in clinical trials
• Neuroprotective potential — Preclinical research suggests GIP receptor activation may have protective effects on brain neurons, though this requires further human study

Glucagon Receptor Activation: Retatrutide’s Unique Advantage

The glucagon receptor is what sets retatrutide apart from every other weight loss medication currently available or in late-stage development. Glucagon is a hormone produced by alpha cells in the pancreas, and it has effects that are essentially opposite to insulin in terms of blood sugar regulation. Its effects on the liver and on energy balance make it a powerful addition for weight management:

• Added calorie burn in animal studies — In obese mice, adding glucagon receptor activation to GIP and GLP-1 increased energy expenditure on top of reduced food intake (Coskun et al., Cell Metabolism, 2022). In people, the clearest signal so far is in the liver: in the Phase 2 liver-fat substudy, β-hydroxybutyrate, a blood marker of fat burning, rose two- to threefold on doses of 4 mg and higher (Sanyal et al., Nature Medicine, 2024)
• Enhanced hepatic fat oxidation — Glucagon stimulates the liver to break down stored fat (lipids) and convert them into energy through a process called beta-oxidation. This is particularly relevant for individuals with non-alcoholic fatty liver disease (NAFLD), a common comorbidity of obesity
• Reduced hepatic lipid accumulation — By promoting fat breakdown in the liver, glucagon receptor activation helps reduce liver fat content — a finding observed in retatrutide clinical trials

The addition of glucagon receptor activation means retatrutide does not rely solely on appetite suppression and reduced caloric intake. It adds a third pathway aimed at how the body uses stored fat, starting with the liver.

The Synergistic Effect: Why Three Pathways Matter

The power of retatrutide lies not just in activating three individual pathways but in how these pathways interact synergistically:

• GLP-1 reduces appetite and slows digestion — you eat less
• GIP improves how your body handles the food you do eat — better insulin response and fat metabolism
• Glucagon drives fat breakdown in the liver — and in animal studies, added calorie burn

This creates a comprehensive metabolic shift that addresses obesity from multiple angles simultaneously. Prior medications relied primarily on reducing caloric intake through appetite suppression; retatrutide adds a pathway aimed at stored fat itself.

Clinical Trial Results

Phase 2 Trial (Published in the New England Journal of Medicine, 2023)

The landmark phase 2 trial of retatrutide, published by Jastreboff et al. in the New England Journal of Medicine (2023), enrolled 338 adults with obesity (BMI 30 or higher) or overweight (BMI 27–30) with at least one weight-related condition. Participants were randomized to receive retatrutide at doses of 1, 4, 8, or 12 mg weekly, or placebo, for 48 weeks.

Key findings:

• 12 mg dose: Average weight loss of 24.2% of body weight (approximately 58 lbs for a 240 lb individual)
• 8 mg dose: Average weight loss of 22.8%
• 4 mg dose: Average weight loss of 17.1%
• 1 mg dose: Average weight loss of 8.7%
• Placebo: Average weight loss of 2.1%
• On 12 mg, every participant lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15% (placebo: 27%, 9% and 2%)
• Waist circumference fell by 19.6 cm on 12 mg, versus 2.6 cm on placebo
• Improvements in blood pressure and lipid profiles were observed across dose groups

Phase 3 Trials (TRIUMPH and TRANSCEND, 2025–2026)

Eli Lilly has reported results from five Phase 3 trials:

• TRIUMPH-1 — 2,339 adults with obesity or overweight and no diabetes, 80 weeks: average weight loss of 28.3% on 12 mg, 25.9% on 9 mg and 19.0% on 4 mg, versus 2.2% on placebo. Nearly half (45.3%) of the 12 mg group lost at least 30% of their body weight, and waist size fell by 24.1 cm.
• TRIUMPH-4 — 445 adults with obesity and knee osteoarthritis, 68 weeks: 28.7% average weight loss on 12 mg, with knee pain scores down about 76% on 9 mg.
• TRIUMPH-2 — 1,152 adults with type 2 diabetes, 80 weeks: 20.8% average weight loss on 12 mg, with HbA1c down 1.4 to 1.6 points.
• TRIUMPH-3 — 1,949 adults with severe obesity and established cardiovascular disease, 80 weeks: 22.6% average weight loss on 12 mg.
• TRANSCEND-T2D-1 (The Lancet, 2026) — 537 adults with type 2 diabetes, 40 weeks: 15.3% weight loss and an HbA1c reduction of 1.94 points on 12 mg.

The headline TRIUMPH figures are Lilly’s efficacy estimand (participants who stayed on treatment); counting everyone randomized, TRIUMPH-1’s 12 mg result was 25.0%.

Phase 2 Trial in Type 2 Diabetes

A separate phase 2 trial evaluated retatrutide in adults with type 2 diabetes and obesity (Rosenstock et al., Lancet, 2023). Results showed:

• HbA1c reduction of up to 2.02% at the 12 mg dose
• Body weight reduction of up to 16.9% at 36 weeks
• In a body-composition (DXA) substudy, total fat mass fell 23.2% on 12 mg and 26.1% on 8 mg at 36 weeks (Coskun et al., Lancet Diabetes & Endocrinology, 2025)

Liver Fat Reduction

One of the most clinically significant secondary findings from retatrutide trials has been its effect on liver fat. Non-alcoholic fatty liver disease affects an estimated 25% of the global population and is the leading cause of liver transplantation. In an MRI substudy of the Phase 2 obesity trial — 98 adults without diabetes who had at least 10% liver fat — retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks, and 86% of those participants reached normal liver fat (under 5%), versus none on placebo (Sanyal et al., Nature Medicine, 2024). Fat around the organs (visceral fat) fell by up to 48% at 48 weeks in the same substudy.

How Retatrutide Compares to Other Weight Loss Medications

Retatrutide’s Phase 2 result came from a shorter trial (48 weeks) than semaglutide’s (68 weeks) and tirzepatide’s (72 weeks), and longer treatment produced more: at 80 weeks in TRIUMPH-1 the 12 mg average reached 28.3%. These are separate trials in different populations; the head-to-head trial against tirzepatide, TRIUMPH-5, is still running.

Timeline of Results: What to Expect

Weeks 1–4 (Initiation Phase)

• Appetite suppression becomes noticeable within 1–2 weeks
• Mild gastrointestinal side effects are common (nausea, bloating)
• Weight loss begins, typically 2–5 lbs during the first month
• Energy levels may fluctuate as the body adjusts

Weeks 4–12 (Dose Escalation)

• Dose increases at regular intervals based on tolerability
• Weight loss accelerates to approximately 1.5–3 lbs per week
• Hunger and food noise decrease significantly
• Blood sugar stabilization becomes apparent
• Clothing begins to fit noticeably differently

Weeks 12–24 (Active Weight Loss Phase)

• Weight loss continues at a steady pace
• Body composition changes become visible — reduced abdominal fat, improved waist-to-hip ratio
• Metabolic markers improve (fasting glucose, triglycerides, cholesterol)
• Energy and physical endurance increase
• Side effects typically stabilize or resolve

Weeks 24–48 and Beyond

• Continued weight loss, though the rate may gradually decelerate
• Significant improvements in cardiovascular risk factors
• Enhanced liver health metrics
• Overall metabolic health transformation

Potential Side Effects

Clinical trial data shows that retatrutide’s side effect profile is similar to other incretin-based medications, with gastrointestinal effects being most common:

Common Side Effects

• Nausea — reported by 16–43% of participants (dose-dependent), most common during dose escalation
• Diarrhea — reported by 15–25%
• Vomiting — reported by 8–15%
• Constipation — reported by 6–12%
• Decreased appetite — common and often considered a therapeutic effect
• Abdominal discomfort — typically mild and transient

Less Common Effects

• Fatigue and dizziness during early treatment
• Injection site reactions (redness, mild swelling)
• Increased heart rate (dose-dependent increases that peaked around week 24 and then declined in trials)

Serious Risks (Rare)

• Pancreatitis (very rare in clinical trials)
• Gallbladder disease associated with rapid weight loss
• Potential thyroid concerns (GLP-1 receptor agonist class warning based on rodent studies)

Most side effects are transient and improve with time, particularly as the body adapts to each new dose level. Gradual dose titration — the standard clinical approach — significantly reduces the severity and frequency of adverse effects.

Who Is a Good Candidate for Retatrutide?

Based on current clinical trial data and the medication’s mechanism of action, retatrutide may be particularly beneficial for:

• Individuals who need substantial weight loss (Rewind does not use a BMI cutoff; your provider decides from your labs, health history and goals)
• People with type 2 diabetes seeking both glycemic control and weight reduction
• Patients with non-alcoholic fatty liver disease — the liver fat reduction data is among the most impressive for any medication
• Individuals with insulin resistance or metabolic syndrome — the comprehensive metabolic effects address multiple aspects of metabolic dysfunction

Retatrutide may not be appropriate for:

• Individuals with a history of medullary thyroid carcinoma or MEN2 syndrome
• Patients with severe gastrointestinal disorders
• Pregnant or breastfeeding women
• Those with a history of pancreatitis
• Individuals with certain endocrine or thyroid conditions

A comprehensive medical evaluation including laboratory testing is essential before starting any weight loss medication. Our peptide therapy programs include thorough screening to ensure you are a safe candidate.

Frequently Asked Questions

Is retatrutide FDA-approved?

Not yet. Eli Lilly has reported results from five Phase 3 trials and plans to submit retatrutide for U.S. approval in the first quarter of 2027.

Can retatrutide be combined with other medications?

Clinical trial protocols studied retatrutide as a standalone treatment. Combination use with other GLP-1 agonists or weight loss medications has not been studied and is not recommended without physician guidance. However, retatrutide can generally be used alongside medications for blood pressure, cholesterol, and other conditions.

What diet should I follow on retatrutide?

A high-protein diet (0.7–1.0 grams per pound of ideal body weight) is recommended to preserve lean muscle mass during rapid weight loss. Adequate hydration, fiber intake, and regular meals help manage gastrointestinal side effects. Your physician or dietitian can provide individualized nutritional guidance.

Personalized Treatment at Rewind Anti-Aging of Miami

At Rewind Anti-Aging of Miami, we stay at the forefront of metabolic medicine, offering our patients access to the most advanced weight management therapies available. Our comprehensive approach includes thorough medical evaluation and laboratory testing, personalized treatment protocols with careful dose titration, nutritional guidance and exercise programming to optimize results and preserve muscle mass, regular progress monitoring with lab work and body composition assessments, and ongoing physician oversight throughout your treatment journey.

Whether retatrutide, tirzepatide, semaglutide, or a combination approach is right for you depends on your individual health profile, goals, and medical history. Book a consultation with our team to discuss which treatment pathway aligns best with your needs.

Related Articles

• Retatrutide Dosage: A Complete Guide to Titration
• Retatrutide vs Semaglutide: Comparing Weight Loss Results
• Retatrutide Weight Loss: What to Know

---

Interested in next-generation weight loss therapy? Rewind Anti-Aging of Miami offers personalized medical weight loss therapy with access to the latest peptide therapy options. Schedule a consultation →

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Weight loss medications should only be used under the supervision of a qualified healthcare provider. Individual results vary. Always consult with your physician before starting any new treatment.